Sunday, November 15, 2026SubscribeMastheadAbout
Cali ReporterCalifornia · National · West Coast · Good News

Advertisement

Explainers

At-Home HPV Testing for Cervical Cancer Prevention

At-home HPV testing is being implemented as a strategy to increase cervical cancer screening rates, particularly in rural areas of the United States.

Portrait of Cali Reporter Explainers Writer
Explainers · November 15, 2026
Share

AI-generated editorial illustration from an imagined camera angle.
AI-generated editorial illustration from an imagined camera angle. Source image: theconversation.com.

Rural women in the United States have a 25% higher rate of cervical cancer and a 42% higher rate of death from the disease compared to urban women. In Colorado, rural counties such as Prowers, Moffat and Montrose have almost three times the rate of cervical cancer than urban counties. Nationwide, 13,000 women are diagnosed with the disease and more than 4,000 die from it each year (1). In Colorado, the most recent data available indicated that almost 150 women were diagnosed with cervical cancer in 2023, and, on average, more than 40 women die annually. [1]

In 2025, the U.S. Food and Drug Administration authorized the Teal Wand for at-home self-collection. Federal and medical organizations have since included self-collection as part of routine screening recommendations. Women can now also do a test during a visit to their primary care doctor even if that doctor does not perform pelvic exams (2). [2]

Studies have shown that when FDA-approved HPV tests are used, self-collected samples are as reliable as clinician-collected samples for detecting cervical precancer. Screening early for cervical cancer can help find precancer disease. Studies show that self-collection tests for HPV can help decrease barriers to care for rural communities (1). [1]

Rural women in the United States have a 25% higher rate of cervical cancer and a 42% higher rate of death from the disease compared to urban women. In Colorado, rural counties such as Prowers, Moffat, and Montrose have almost three times the rate of cervical cancer than urban counties. These disparities are exacerbated by limited access to regular screenings, with rural women being 20% less likely to be up to date on cervical cancer screening (Source ID: 1). [1]

Advertisement

In 2025, the U.S. Food and Drug Administration authorized the Teal Wand for at-home self-collection of vaginal specimens for use in an approved HPV molecular assay. This approval was granted as part of a De Novo classification process, which determined that the device is safe and effective for home use (Source ID: 2). [2]

Studies have shown that when FDA-approved HPV tests are used, self-collected samples are as reliable as clinician-collected samples for detecting cervical precancer. This reliability is critical for expanding access to screening, particularly in rural areas where access to healthcare facilities is limited. The development of at-home tests is a significant step toward addressing these disparities (Source ID: 1). [1]

Rural women in the United States have a 25% higher rate of cervical cancer and a 42% higher rate of death from the disease compared to urban women. In Colorado, rural counties such as Prowers, Moffat, and Montrose have almost three times the rate of cervical cancer than urban counties. These disparities are partly due to limited access to healthcare facilities and lower screening rates, as rural women are 20% less likely to be up to date on cervical cancer screening (Source ID: 1). [1]

In 2025, the U.S. Food and Drug Administration authorized the Teal Wand for at-home self-collection, which allows women to collect vaginal samples using a simple swab that is then mailed to a laboratory for HPV testing. Federal and medical organizations have since included self-collection as part of routine screening recommendations. Studies have shown that when FDA-approved HPV tests are used, self-collected samples are as reliable as clinician-collected samples for detecting cervical precancer (Source ID: 1). [1]

Advertisement

The FDA's authorization of the Teal Wand for home use was granted under De Novo classification number DEN240045. This decision was made by the FDA's Microbiology Review Advisory Committee and classified the device under Product Code SEP. The device is intended for home collection and transport of vaginal specimens by lay users for use in an approved HPV molecular assay (Source ID: 2). [2]

Sources

The Conversation – Articles (US)

www.accessdata.fda.gov

Prepared with AI assistance from the cited sources.

The Cali Reporter newsletter

The stories worth your time.

California, the country, and what comes next. Join our free newsletter for reporting that keeps you informed.

By joining, you agree to receive the Cali Reporter newsletter. Unsubscribe at any time. Privacy policy.

More in Explainers

Advertisement